|
|
Blood, 1 September 2004, Vol. 104, No. 5, pp. 1428-1434.
Prepublished online as a Blood First Edition Paper on May 11, 2004; DOI 10.1182/blood-2003-09-3236.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
Andreas Rosenwald,
Eric Y. Chuang,
R. Eric Davis,
Adrian Wiestner,
Ash A. Alizadeh,
Diane C. Arthur,
James B. Mitchell,
Gerald E. Marti,
Daniel H. Fowler,
Wyndham H. Wilson, and
Louis M. Staudt
From the Metabolism Branch, Radiation Biology Branch, and Experimental Immunology and Transplantation Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD; the Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD; the Division of Gene and Cell Therapy, Food and Drug Administration/Center for Biologics Evaluation and Research (FDA/CBER), NIH, Bethesda, MD; and the Department of Biochemistry, Stanford University School of Medicine, Stanford, CA.
Fludarabine, the current standard treatment for B-cell chronic lymphocytic leukemia (CLL), can induce apoptosis in CLL cells in vitro, and a number of molecular mechanisms contribute to its cytotoxicity. Using gene expression profiling, we investigated the molecular consequences of fludarabine treatment of patients with CLL in vivo. In 7 patients with CLL, a consistent gene expression signature of in vivo fludarabine exposure was identified. Many of the fludarabine signature genes were known p53 target genes and genes involved in DNA repair. In vitro treatment of CLL cells with fludarabine induced the same set of genes as observed in vivo, and many of these genes were also induced by in vitro exposure of CLL cells to ionizing radiation. Using isogenic p53 wild-type and null lymphoblastoid cell lines, we confirmed that many of the fludarabine signature genes were also p53 target genes. Because in vivo treatment with fludarabine induces a p53-dependent gene expression response, fludarabine treatment has the potential to select p53-mutant CLL cells, which are more drug resistant and associated with an aggressive clinical course. These considerations suggest that fludarabine treatment should be given in strict accordance to the current National Cancer Institute (NCI) guidelines that have established criteria of disease activity that warrant treatment.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Y. H. Hallaert, A. Jaspers, C. J. van Noesel, M. H. J. van Oers, A. P. Kater, and E. Eldering
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches
Blood,
December 15, 2008;
112(13):
5141 - 5149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lopez-Guerra, L. Trigueros-Motos, M. Molina-Arcas, N. Villamor, F. J. Casado, E. Montserrat, E. Campo, D. Colomer, and M. Pastor-Anglada
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells
Haematologica,
December 1, 2008;
93(12):
1843 - 1851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kujawski, P. Ouillette, H. Erba, C. Saddler, A. Jakubowiak, M. Kaminski, K. Shedden, and S. N. Malek
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia
Blood,
September 1, 2008;
112(5):
1993 - 2003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hewamana, S. Alghazal, T. T. Lin, M. Clement, C. Jenkins, M. L. Guzman, C. T. Jordan, S. Neelakantan, P. A. Crooks, A. K. Burnett, et al.
The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
Blood,
May 1, 2008;
111(9):
4681 - 4689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Hauswirth and U. Jager
Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia
Haematologica,
January 1, 2008;
93(1):
14 - 19.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Gine, M. Crespo, A. Muntanola, E. Calpe, M. J. Baptista, N. Villamor, E. Montserrat, and F. Bosch
Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment
Haematologica,
January 1, 2008;
93(1):
75 - 82.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Young, D. D. Weisenburger, B. J. Dave, L. Smith, W. Sanger, J. Iqbal, E. Campo, J. Delabie, R. D. Gascoyne, G. Ott, et al.
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma
Blood,
December 15, 2007;
110(13):
4396 - 4405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Austen, A. Skowronska, C. Baker, J. E. Powell, A. Gardiner, D. Oscier, A. Majid, M. Dyer, R. Siebert, A. M. Taylor, et al.
Mutation Status of the Residual ATM Allele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q Deletion
J. Clin. Oncol.,
December 1, 2007;
25(34):
5448 - 5457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Knoops, R. Haas, S. de Kemp, D. Majoor, A. Broeks, E. Eldering, J. P. de Boer, M. Verheij, C. van Ostrom, A. de Vries, et al.
In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma
Blood,
August 15, 2007;
110(4):
1116 - 1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, T. E. Witzig, S. R. Fink, R. B. Jenkins, S. F. Paternoster, S. A. Smoley, K. J. Stockero, D. M. Nast, H. C. Flynn, R. C. Tschumper, et al.
Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
October 1, 2006;
24(28):
4634 - 4641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kojima, M. Konopleva, T. McQueen, S. O'Brien, W. Plunkett, and M. Andreeff
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
Blood,
August 1, 2006;
108(3):
993 - 1000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Secchiero, E. Barbarotto, M. Tiribelli, C. Zerbinati, M. G. di Iasio, A. Gonelli, F. Cavazzini, D. Campioni, R. Fanin, A. Cuneo, et al.
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Blood,
May 15, 2006;
107(10):
4122 - 4129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Bryant and T. Helleday
Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair
Nucleic Acids Res.,
March 23, 2006;
34(6):
1685 - 1691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch
How I treat refractory CLL
Blood,
February 15, 2006;
107(4):
1276 - 1283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Austen, J. E. Powell, A. Alvi, I. Edwards, L. Hooper, J. Starczynski, A. M. R. Taylor, C. Fegan, P. Moss, and T. Stankovic
Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL
Blood,
November 1, 2005;
106(9):
3175 - 3182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Alvi, B. Austen, V. J. Weston, C. Fegan, D. MacCallum, A. Gianella-Borradori, D. P. Lane, M. Hubank, J. E. Powell, W. Wei, et al.
A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival
Blood,
June 1, 2005;
105(11):
4484 - 4491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
